



Update for the Quarter Ending 30 September 2019

Brisbane, Australia, 30 October 2019 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to provide an update on the company's activities for the first quarter ended September 30, 2019.

"We have made significant progress this quarter by securing important regulatory approvals for ResAppDx-EU in Europe and Australia. These approvals result from years of hard work by the team and they unlock the commercialisation of our first product in these regions," said Tony Keating, CEO and Managing Director of ResApp. "We also received excellent results from our at-home sleep apnoea study which demonstrated that our algorithms perform just as well in a patient's own home as they did in the sleep laboratory – allowing us to progress commercialisation. We now look forward to a transition in the company as we build and validate our global sales and marketing strategies for ResAppDx."

Recent Highlights and Outlook

- **Secured regulatory approvals for ResAppDx-EU in Europe and Australia.** During the quarter, ResApp received CE Mark certification for ResAppDx-EU, the world's first smartphone-based diagnostic test for respiratory disease in adults and children. CE Mark certification indicates that ResAppDx-EU meets the essential requirements of all the applicable European regulations as a class IIa medical device and allows for its sale throughout the European Economic Area. ResAppDx-EU also received Australian Therapeutic Goods Administration (TGA) approval for paediatric use and is now listed on the Australian Register of Therapeutic Goods allowing for its sale in Australia. The company has submitted an application to the TGA for adult use and a De Novo application for paediatric use is under review by the US Food and Drug Administration (FDA).
- **Positive results from prospective at-home sleep apnoea study.** In September, ResApp released positive results from its prospective, at-home sleep apnoea study demonstrating that ResApp's algorithms, which analyse a person's breathing and snoring sounds recorded using a smartphone placed on a bedside table, were able to accurately identify obstructive sleep apnoea when compared to a simultaneous at-home sleep study. For the three AHI thresholds under consideration (representing mild, moderate, and severe sleep apnoea) the area under the receiver operating characteristic curve was greater than 0.91, sensitivity was between 83-85%, and specificity was between 73-90%.
- **Joined Startup Creasphere program.** In October, ResApp announced that it had been selected to join the Startup Creasphere digital health program in Munich. Startup Creasphere is a twelve-week program in which ResApp will work with subject matter experts and mentors from the consumer healthcare business unit of Sanofi to explore opportunities to co-create

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T +61 7 3724 0035 E info@resapphealth.com.au W www.resapphealth.com.au



consumer health-focused respiratory disease products. The Kick-off and Orientation sessions were held in October, with the first Deep Dive week to take place in mid-November.

- **Progress on DARPA WASH program.** ResApp received additional funding from Lockheed Martin during the quarter and continues to collaborate on the Defense Advanced Research Projects Agency (DARPA) Warfighter Analytics using Smartphones for Health (WASH) program.
- **Data from Australian adult clinical study presented.** Results from ResApp's Australian adult clinical study were recently presented at the European Respiratory Society (ERS) International Congress 2020 in Madrid, Spain. ERS is the largest respiratory-focused medical conference in Europe, with over 20,000 delegates attending each year. Additional data from the study will be presented at the 24th Congress of the Asian Pacific Society of Respirology in Vietnam in November.
- **Asthma severity research accepted for publication.** A publication titled, "*Stratifying asthma severity in children using cough sound analytic technology*" has been accepted for publication in the peer-reviewed medical journal, *The Journal of Asthma*. The publication, authored by our partners at The University of Queensland and Joondalup Health Campus, investigates the use of cough sounds to measure asthma severity in children.
- **Increased presence at healthcare industry events.** In October, the company attended the 11th Annual Connected Health Conference in Boston where Tony Keating, CEO and Managing Director participated in the panel discussion, *Vocal Biomarkers: New Evidence and Market Opportunities*. The company also attended HLTH 2019 in Las Vegas, one of the largest conferences for health innovation with over 6,000 attendees. At HLTH, Tony participated in the panel discussion, *Putting Consumers in the Driver's Seat: New Models, High Speed Lanes and Road Blocks Ahead* organised by the American Telemedicine Association. ResApp will also present in London at the Digihealth Leaders conference in November.
- **Strong balance sheet to advance ResApp through commercialisation.** The company held cash of \$3.8 million as of September 30, 2019. ResApp recently filed its FY2019 tax return with the Australian Tax Office and expects to receive a \$1.8 million R&D tax incentive cash rebate. A significant proportion of ResApp's R&D spend for the current (FY2020) financial year will also be eligible for the R&D tax incentive.

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infection, pneumonia, bronchiolitis,

ResApp Health Limited ABN 51 094 468 318

Level 12, 100 Creek St, Brisbane QLD 4000 Australia

T +61 7 3724 0035 E info@resapphealth.com.au W www.resapphealth.com.au



croup, asthma exacerbation/reactive airway disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation and obstructive sleep apnoea. ResApp's smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

ResApp Health Limited

ABN

51 094 468 318

Quarter ended ("current quarter")

30 September 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	56	56
1.2 Payments for		
(a) research and development	(628)	(628)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(83)	(83)
(d) leased assets	-	-
(e) staff costs	(702)	(702)
(f) administration and corporate costs	(340)	(340)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	23	23
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	34	34
1.8 Other – R&D rebate	-	-
1.9 Net cash from / (used in) operating activities	(1,640)	(1,640)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
(d) intellectual property	-	-
(e) other non-current assets	(104)	(104)
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(104)	(104)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	-
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	-
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	-	-

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	5,516	5,516
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(1,640)	(1,640)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(104)	(104)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	3,772	3,772

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3,772	5,516
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,772	5,516

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	(135)
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
	<ol style="list-style-type: none"> 1. Director fees, salary and super; and 2. Consultancy fees. 	

7.	Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1	Aggregate amount of payments to these parties included in item 1.2	
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--


9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(854)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	(123)
9.4 Leased assets	-
9.5 Staff costs	(755)
9.6 Administration and corporate costs	(148)
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	(1,880)

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:


.....
(Director)

Date: 30 October 2019

Print name: Tony Keating

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.